Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | FAP | Q12884 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9394937 | 1.00 | TAAR1 (0.46) | TAAR1IDO1GRB2KIF11KMT2A | |
| SCHEMBL2269567 | 1.00 | TAAR1 (0.46) | TAAR1IDO1GRB2KIF11KMT2A | |
| SCHEMBL2927263 | 0.81 | TAAR1 (0.46) | TAAR1IDO1GRB2KIF11KMT2A | |
| SCHEMBL29162871 | 0.81 | TAAR1 (0.46) | TAAR1IDO1GRB2KIF11KMT2A | |
| SCHEMBL4624617 | 0.80 | HTR2A (0.66) | TAAR1IDO1DPP4DPP8DPP9 | |
| SCHEMBL4624614 | 0.80 | HTR2A (0.66) | TAAR1IDO1DPP4DPP8DPP9 | |
| SCHEMBL2268272 | 0.79 | LOXL2 (0.43) | TAAR1IDO1DPP4FAPDPP8 | |
| SCHEMBL3393051 | 0.79 | LOXL2 (0.43) | TAAR1IDO1DPP4FAPDPP8 | |
| SCHEMBL2182249 | 0.79 | LOXL2 (0.43) | TAAR1IDO1DPP4FAPDPP8 | |
| SCHEMBL6141118 | 0.78 | ALDH1A1 (0.44) | TAAR1IDO1KIF11KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0182262-B1 | NONA AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-01-20 | — | — | EP | claimed |
| US-5116817-A | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1992-05-26 | — | — | US | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| US-4851385-A | LUTEINIZING HORMONE RELEASING HORMONE | INDIANA UNIVERSITY FOUNDATION (US) | 1989-07-25 | — | — | US | claimed |
| EP-0097031-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1988-09-21 | — | — | EP | claimed |
| EP-0111841-B1 | LHRH PREPARATIONS FOR INTRANASAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1987-05-06 | — | — | EP | claimed |
| EP-0182262-A2 | Nona and decapeptide analogs of LHRH useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1986-05-28 | — | — | EP | claimed |
| EP-0002236-B1 | PEPTIDES, THEIR SALTS, THEIR ACID ADDITION SALTS, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USE AS MORPHINE ANTAGONISTS AND ANAESTHETICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | claimed |
| US-4481190-A | LUTEINIZING HORMONE RELEASING HORMONE | SYNTEX (U.S.A.) INC. (US) | 1984-11-06 | — | — | US | claimed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | claimed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-5376635-A | A polypeptides as diuretics, hypotensive agents | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-12-27 | — | — | US | disclosed |
| US-4481190-A | LUTEINIZING HORMONE RELEASING HORMONE | SYNTEX (U.S.A.) INC. (US) | 1984-11-06 | — | — | US | disclosed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | disclosed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | TAAR1 478/4885IDO1 896/4885GRB2 4821/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | TAAR1 478/4885IDO1 896/4885GRB2 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.